Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Worst Type of Colon Cancer: 7 Types Compared for Prognosis and Risk
Worst Type of Colon Cancer: 7 Types Compared for Prognosis and Risk 2

Colon cancer is a complex disease with many types. Each type has its own impact on prognosis and risk. At Liv Hospital, we focus on understanding these differences to offer the best care.

Right-sided colon cancer is often seen as having a worse prognosis than left-sided colon cancer. It’s important for patients to know their exact diagnosis.

We are dedicated to patient-centered care. We guide our patients through the complexities of their condition with compassion and expertise.

Key Takeaways

  • Colon cancer has multiple types with different prognoses.
  • Right-sided colon cancer often has a poorer prognosis.
  • Understanding the specific type of colon cancer is key for effective treatment.
  • Liv Hospital provides internationally benchmarked care for colon cancer patients.
  • Patient-centered care is our priority in treating colon cancer.

Understanding Colon Cancer Basics

Doctor and patient discussing perfect health exam results friendly physician is explaining something to young woman medicine concept
Worst Type of Colon Cancer: 7 Types Compared for Prognosis and Risk 3

Knowing the basics of colon cancer is key for patients to make smart choices about their care. Colon cancer starts with genetic changes and is influenced by our environment.

How Colon Cancer Develops

Colon cancer often starts as a harmless polyp in the colon or rectum. Over time, this polyp can turn cancerous due to genetic changes. The process involves multiple steps, including initiation, promotion, and progression. Our diet and lifestyle also play a big role in this change.

“The development of colon cancer is a multifactorial process, involving both genetic predisposition and environmental influences.”

Staging and Its Impact on Prognosis

The stage of colon cancer is very important for knowing what to expect and how to treat it. The TNM system is used to stage it. It looks at the tumor size (T), lymph nodes (N), and if it has spread (M).

StageDescriptionFive-Year Survival Rate
ICancer is limited to the colon or rectum90%
IICancer has grown through the wall of the colon or rectum70-80%
IIICancer has spread to nearby lymph nodes40-60%
IVCancer has metastasized to distant organs10-20%

Key Risk Factors

There are several key risk factors for colon cancer. These include:

  • Age: Risk increases after 50
  • Family history of colon cancer
  • Genetic syndromes such as Lynch syndrome
  • Diet high in red and processed meat
  • Obesity and lack of physical activity

Knowing these risk factors can help in catching colon cancer early. We suggest regular screening for those at high risk.

Right-Sided vs. Left-Sided Colon Cancer

African american guy having stomach ache after eating touching aching stomach suffering from pain sitting on sofa at home
Worst Type of Colon Cancer: 7 Types Compared for Prognosis and Risk 4

Knowing the difference between right-sided and left-sided colon cancer is key for treatment. The colon is part of our digestive system, which gets waste ready to leave our body. Where the cancer is found affects how it’s treated and the patient’s chances of recovery.

Anatomical Differences Explained

The colon is split into sections, like the ascending colon (right) and descending colon (left). Right-sided colon cancer happens in the cecum and parts of the transverse colon. On the other hand, left-sided colon cancer is found in the left transverse colon, descending, sigmoid, and rectum.

The right and left colon parts come from different beginnings in the body. The right colon is wider, while the left is narrower and more likely to cause blockages.

Why Location Matters for Prognosis

The place where colon cancer starts greatly affects its outcome. Right-sided colon cancer often has a worse outlook than left-sided colon cancer. This is because of differences in how the cancer grows, when it’s found, and how well it responds to treatment.

Right-sided cancers are usually found later because they can grow big without causing blockages. This makes them harder to catch early.

Survival Rate Disparities by Location

Survival chances for colon cancer depend on where the tumor is. People with left-sided cancer usually live longer than those with right-sided. This is because of differences in the cancer itself and when it’s found.

Doctors need to understand these differences to give the best treatment for each patient, based on where their cancer is.

Identifying the Worst Type of Colon Cancer

Knowing the worst type of colon cancer is key for planning treatment. Colon cancer is not just one disease. It has many types, each with its own treatment challenges.

Criteria for Determining Severity

The severity of colon cancer depends on several factors. These include the stage at diagnosis, the tumor’s location, and its type. Advanced stage at diagnosis and aggressive histological types usually mean a poorer outcome.

The location of the tumor in the colon is also very important. The colon is divided into sections. Where the tumor is can greatly affect the prognosis.

Right-Sided Colon Cancer’s Poor Prognosis

Right-sided colon cancer happens in the ascending colon. It’s often found later than left-sided colon cancer. This late discovery, along with its unique molecular traits, leads to a poor prognosis.

Patients with right-sided colon cancer face a higher risk of the cancer coming back and spreading. Getting treatment quickly and effectively is very important.

Five-Year Survival Rate Comparisons

Looking at the five-year survival rates for different types of colon cancer gives us important insights. Generally, right-sided colon cancers have lower survival rates than left-sided ones.

  • Right-sided colon cancer: 60-65% five-year survival rate
  • Left-sided colon cancer: 70-75% five-year survival rate

Understanding these differences helps us tailor treatments better. This can improve patient outcomes.

Adenocarcinoma: The Most Common Form

Adenocarcinoma is the most common type of colon cancer, making up most cases. It starts in the glandular cells of the colon. Knowing about it helps us treat it better.

Cellular Characteristics

Adenocarcinoma cells come from glandular tissue and often make mucin. Their structure affects how the tumor grows and reacts to treatment. We study these cells to figure out how aggressive the cancer is and what treatment to use.

Key cellular features include:

  • Glandular formation
  • Mucin production
  • Variability in differentiation

Typical Progression Pattern

Adenocarcinoma grows in stages, from small to big tumors that can spread. Knowing this helps us catch it early and treat it right. We check the tumor’s stage to choose the best treatment.

The typical progression involves:

  1. Local invasion
  2. Lymph node involvement
  3. Distant metastasis

Treatment Response and Outlook

How well adenocarcinoma responds to treatment depends on several factors. We look at these when planning treatment, which might include surgery, chemo, or targeted therapy.

Treatment ModalityResponse RateOutcomes
SurgeryHighCurative in early stages
ChemotherapyVariablePalliative or adjuvant
Targeted TherapySpecific to molecular markersImproved survival in selected cases

A leading oncologist says, “Knowing adenocarcinoma well helps us tailor treatment for each patient. This improves care for colon cancer.”

“The variety in adenocarcinoma means we need a custom treatment plan. This includes the newest in molecular tests and treatments.”

We keep learning about adenocarcinoma. This helps us better diagnose and treat this common colon cancer type.

Mucinous Adenocarcinoma

Mucinous adenocarcinoma is a type of colon cancer that makes a lot of mucin. This affects how it acts, how it’s diagnosed, and how it responds to treatment. We’ll look into what mucin production means, the challenges in diagnosing it, and how it impacts treatment and prognosis.

Mucin Production and Its Effects

Mucinous adenocarcinoma is known for making a lot of mucin, a protein that’s part of the tumor. This mucin can make the tumor look different on scans and under the microscope. Because of the mucin, it can be hard to find the cancer cells, which can make diagnosis tricky.

The mucin in the tumor can also change how aggressive it is. Some studies say it might make the cancer grow faster or not respond well to some treatments. It’s important to understand how mucin works to find the best ways to treat it.

Diagnostic Challenges

Diagnosing mucinous adenocarcinoma is hard because of its unique features. The mucin can hide the cancer cells, making it tough to get a clear diagnosis from a biopsy. Using advanced imaging and detailed microscopic exams is key to getting the right diagnosis.

“The diagnosis of mucinous adenocarcinoma requires a high index of suspicion and thorough pathological evaluation to distinguish it from other types of colon cancer.”

Prognosis and Treatment Considerations

The outlook for mucinous adenocarcinoma can depend on several things, like how far along the cancer is and how much mucin it makes. Generally, it’s seen as having a worse prognosis than other colon cancers because it often gets diagnosed later.

When treating mucinous adenocarcinoma, doctors might use surgery, chemotherapy, or targeted therapy. The mucin in the tumor can affect how well these treatments work, so treatment plans need to be tailored for each patient.

CharacteristicsMucinous AdenocarcinomaOther Colon Cancer Types
Mucin ProductionSignificantVariable
Diagnostic ChallengesHigh due to mucin obscuring malignant cellsVariable
PrognosisGenerally poorerVariable depending on type and stage

Signet Ring Cell Carcinoma

Signet ring cell carcinoma is a rare and aggressive form of colon cancer. It is challenging to diagnose and treat. This type of colon cancer grows fast and doesn’t respond well to common treatments.

Aggressive Nature

This cancer type is very aggressive. It spreads deep into the colon wall, making it hard to catch early. Often, it’s found when it’s too late, leading to a poor outlook.

Unique Cellular Appearance

The cancer cells look different under a microscope. They have lots of mucin, pushing the nucleus to the edge. This gives them a “signet ring” look. This look is key for spotting this cancer, as it’s different from other types of colon lesions.

Survival Statistics and Outcomes

The outlook for those with signet ring cell carcinoma is not good. The five-year survival rate is much lower. This is because it’s aggressive and often found late. We aim to improve survival rates by catching it early and using new treatments.

It’s important to understand signet ring cell carcinoma to create better treatment plans. As a rare neoplasm of the large intestine, it needs a special approach to tackle its unique challenges.

Medullary Carcinoma of the Colon

Medullary carcinoma is a rare type of colon cancer. It has unique features and genetic traits. This makes it different from other colon cancers and often leads to a better outcome.

Distinguishing Features

Medullary carcinoma looks different under a microscope. It has solid tumor cells with lots of cytoplasm. These cells are surrounded by many lymphocytes.

This unique look sets it apart from other colon cancers. The many lymphocytes are thought to help it have a better prognosis.

Genetic Associations

Genetics are key in medullary carcinoma. Microsatellite instability (MSI) is a major genetic feature. MSI happens when DNA repair fails, causing many genetic changes.

Medullary carcinoma often has MSI-high status. This is different from most other colorectal cancers, which are microsatellite stable (MSS).

Prognosis Compared to Other Types

Medullary carcinoma usually has a better prognosis than other colon cancers. Studies show patients with this type often live longer. The many lymphocytes and MSI-high status help explain this better outcome.

Knowing these factors is key to managing medullary carcinoma well. It shows why genetic testing is important for treatment plans.

Rare Colon Cancer Types

Most colon cancers are adenocarcinomas, but there are rare types too. These include neuroendocrine tumors, colorectal lymphoma, and gastrointestinal stromal tumors (GISTs). Each type needs its own approach to diagnosis and treatment. Knowing about these rare cancers is key to giving patients the best care.

Neuroendocrine Tumors

Neuroendocrine tumors (NETs) of the colon are rare. They start from neuroendocrine cells, which help make hormones. These tumors can be benign or very aggressive. Early detection is critical for managing them well.

Colorectal Lymphoma

Colorectal lymphoma is a rare cancer of the GI tract. It’s hard to diagnose because it doesn’t show clear symptoms. Accurate diagnosis is vital for the right treatment, which might include chemotherapy and targeted therapy.

Gastrointestinal Stromal Tumors (GISTs)

GISTs are rare tumors in the GI tract, often in the stomach but also in the colon. They come from cells that control digestion. Treatment usually involves surgery and might include drugs that target specific cells.

Understanding rare colon cancers like neuroendocrine tumors, colorectal lymphoma, and GISTs is important. By knowing their unique features, doctors can provide better care.

Genetic Factors Influencing Colon Cancer Outcomes

The genetic makeup of colon cancer greatly affects its growth and how well it responds to treatment. It’s clear that genetics play a big role in how patients do.

Key Mutations: KRAS, BRAF, and MSI Status

Specific genetic changes can greatly impact colon cancer’s treatment and outlook. The KRAS and BRAF genes are often changed in colon cancer. These changes can affect how well the tumor responds to certain treatments.

KRAS changes make some treatments less effective. On the other hand, BRAF changes, like the V600E mutation, can make tumors more sensitive to specific treatments. This is important for choosing the right treatment.

The Microsatellite Instability (MSI) status is also key. Tumors with high MSI (MSI-H) have a different outlook and treatment plan than those with microsatellite stability (MSS) or low MSI (MSI-L).

Genetic MarkerImpact on PrognosisTreatment Implications
KRAS MutationVariableResistance to anti-EGFR therapies
BRAF V600E MutationPoor prognosisPotential sensitivity to targeted therapies
MSI-HFavorable in early-stage diseasePotential benefit from immunotherapy

Hereditary Syndromes and Their Impact

Hereditary syndromes like Lynch Syndrome and FAP raise the risk of colon cancer. Finding these syndromes early is key for early treatment and monitoring.

Lynch Syndrome, caused by DNA mismatch repair gene mutations, increases the risk of colon and other cancers. FAP, with its many colon polyps, often starts in younger people and needs aggressive treatment to stop cancer.

How Genetics Guides Treatment Selection

Genetic testing is now a big part of treating colon cancer. It helps choose the best treatments and find new targets for therapy. By looking at a tumor’s genes, doctors can make treatments more personal, improving results and avoiding unnecessary treatments.

For example, those with BRAF mutations might get targeted therapies. Those with MSI-H tumors might get immunotherapy. Knowing the genetic details of colon cancer helps tailor treatments, improving care for patients.

Conclusion: Advances in Understanding and Treating Colon Cancer

Recent breakthroughs in genetics and treatment have greatly improved colon cancer care. We now focus more on personalized care. This is because we better understand the different types of colon cancer.

Knowing the unique traits of right and left colon cancer helps us tailor treatments. This approach has led to better patient results and outlooks. Personalized care is key to improving health outcomes.

New treatments like targeted and immunotherapies have grown our fight against colon cancer. Survival rates, mainly for early-stage patients, are getting better. These advances are a big step forward.

Future success in colon cancer treatment depends on ongoing research and investment. By deepening our knowledge of colon cancer and creating better treatments, we aim for better lives for those with this disease.

What are the different types of colon cancer?

Colon cancer types include adenocarcinoma, mucinous adenocarcinoma, and signet ring cell carcinoma. Medullary carcinoma and rare types like neuroendocrine tumors also exist.

Why is right-sided colon cancer considered to have a poorer prognosis?

Right-sided colon cancer is often found later and has different genes. This makes it harder to treat than left-sided cancer.

How does the location of colon cancer affect its prognosis?

Where the cancer is located matters. Right and left sides have different symptoms and genetic changes. This affects how well the cancer can be treated.

What is adenocarcinoma, and how does it progress?

Adenocarcinoma starts in glandular cells and is the most common type. It grows from polyps to invasive cancer over time.

What are the characteristics of mucinous adenocarcinoma?

Mucinous adenocarcinoma produces mucin. This can make diagnosis and treatment planning tricky.

Why is signet ring cell carcinoma considered aggressive?

Its unique cells and late diagnosis make signet ring cell carcinoma aggressive. This leads to a worse prognosis.

What are the distinguishing features of medullary carcinoma?

Medullary carcinoma has a unique look and genetic links. Its microsatellite instability can affect its outcome.

How do genetic factors influence colon cancer outcomes?

Genes like KRAS, BRAF, and MSI status are key. They help predict outcomes and guide treatments.

What are the key risk factors for developing colon cancer?

Risk factors include family history, age, lifestyle, and genetic syndromes. These increase the chance of getting colon cancer.

How is colon cancer staged, and why is staging important?

Staging shows how far the cancer has spread. It’s vital for knowing the prognosis and choosing the right treatment.

What are the treatment options for different types of colon cancer?

Treatments vary by cancer type and stage. They include surgery, chemotherapy, and targeted therapy, based on the patient’s needs.

How do rare types of colon cancer, such as neuroendocrine tumors, differ from more common types?

Rare cancers like neuroendocrine tumors have unique features. They need special care and treatment plans.

Reference

Nature. Research Article. https://www.nature.com/articles/s41598-024-63143-3

Turkish Journal of Colorectal Disease. Differences Between Right- and Left-Sided Colon Cancers in Terms of Clinicopathological Features and Long-Term Oncological Outcomes. https://turkishjcrd.com/articles/differences-between-right-and-left-colon-cancers-in-terms-of-clinicopathological-features-and-long-term-oncological-outcomes/tjcd.galenos.2020.2020-4-6

NCBI. PMC article. https://pmc.ncbi.nlm.nih.gov/articles/PMC3072702/

National Cancer Institute (NCI) SEER. Cancer Stat Facts: Colorectal Cancer. https://seer.cancer.gov/statfacts/html/colorect.html

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 26 75